Facts and artefacts of coagulation assays for factor Xa inhibitors.

Abstract

Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of thromboembolic disorders; of these, rivaroxaban, apixaban and edoxaban (DU-176b) are in the most advanced stages of development. Rivaroxaban is approved in several countries for the prevention of venous thromboembolism (VTE) after… (More)
DOI: 10.1160/TH10-01-0080

Topics

1 Figure or Table

Cite this paper

@article{Haas2010FactsAA, title={Facts and artefacts of coagulation assays for factor Xa inhibitors.}, author={Sylvia K Haas}, journal={Thrombosis and haemostasis}, year={2010}, volume={103 4}, pages={686-8} }